CRBN and B-cell non-Hodgkin lymphoma: IKZF1, a driver gene in multiple myeloma and other B-cell lymphomas, is the molecular target of IMiDs (immunomodulatory drugs) including lenalidomide and pomalidomide, which facilitate CRBN-mediated degradation of the Ikaros family proteins [26, 27].